Type 2 diabetes in general practice in Norway 2005–2014: moderate improvements in risk factor control but still major gaps in complication screening

 Åsne Bakke,1,2 John G Cooper,1,3 Geir Thue,2,3 Svein Skeie,4 Siri Carlsen,1,3 Ingvid Dalen,5 Karianne Fjeld Lövås,3 Tone Vonheim Madsen,3 Ellen Renate Oord,1 Tore Julsrud Berg,6,7 Tor Claudi,8 Anh Thi Tran,9 Bjørn Gjelsvik,9 Anne Karen Jenum,9 Sverre Sandberg2,3,10

ABSTRACT

Objective To assess the status of type 2 diabetes care in general practice and changes in the quality of care between 2005 and 2014, and to identify areas of diabetes care requiring improvement.

Research design and methods Two cross-sectional surveys were performed that included patients with type 2 diabetes in selected areas (n=9464 in 2014, n=5463 in 2005). Quality of care was assessed based on key recommendations in national guidelines. Differences in clinical performance between 2005 and 2014 were assessed in regression models adjusting for age, sex, counties and clustering within general practices.

Results Treatment targets were achieved in a higher proportion of patients in 2014 compared with 2005: hemoglobin A1c ≤7.0% (<53 mmol/mol) in 62.8% vs 54.3%, blood pressure ≤135/80 mm Hg in 44.9% vs 36.6%, and total cholesterol ≤4.5 mmol/L in 49.9% vs 33.5% (all adjusted P<0.001). Regarding screening procedures for microvascular complications, fewer patients had recorded an eye examination (61.0% vs 71.5%, adjusted P<0.001), whereas more patients underwent monofilament test (25.9% vs 18.7%, adjusted P<0.001). Testing for albuminuria remained low (30.3%) in 2014 compared with 2005. Quality of care was assessed based on key recommendations in national guidelines. Differences in clinical performance between 2005 and 2014 were assessed in regression models adjusting for age, sex, counties and clustering within general practices.

Conclusions We found moderate improvements in risk factor control for patients with type 2 diabetes in general practice during the last decade, which are similar to improvements reported in other countries. We report major gaps in the performance of recommended screening procedures to detect microvascular complications. The proportion of daily smokers remains high. We suggest incentives to promote further improvements in diabetes care in Norway.

INTRODUCTION

Good glycemic control and appropriate management of cardiovascular risk factors in patients with type 2 diabetes reduce the risk of vascular complications and mortality.1–9 The Steno-2 trial found an increase in lifespan in high-risk patients with type 2 diabetes with a combined behavioral and pharmacological intervention in a specialist care setting. However, in most countries the majority of patients with type 2 diabetes are treated in primary care. The initial 5-year follow-up of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care (ADDITION-Europe) trial of screening-detected patients with type 2 diabetes in general practice found improved risk factor levels and a trend toward a reduced rate of cardiovascular events, microvascular complications and death in the multifactorial treatment group compared...
with routine care. A Swedish observational study with 13 000 patients with type 2 diabetes from general practice in 2012 reported that fatal and non-fatal cardiovascular disease (CVD) decreased from 23.6% to 6.0% when they compared patients achieving a decrease versus an increase in hemoglobin A1c (HbA1c), blood pressure and lipids. It has also been shown that early detection of complications by systematic screening and intervention prevents or delays the development of target organ disease.

Risk factor control and screening for early complications can only be closely monitored in countries with nationwide and comprehensive diabetes registries such as Sweden and Scotland. Other countries must perform cross-sectional surveys to assess status and time trends in diabetes care. In Norway, the quality of type 2 diabetes care has been assessed through repeated cross-sectional surveys (Rogaland-Oslo-Salten-Akershus-Hordaland (ROSA) studies) since 1995. The previous survey, ROSA 3, was performed in 2005 and showed substantial improvements in glycemic, blood pressure and lipid control between 1995 and 2005.

A new assessment of the quality of diabetes care was important for several reasons. First, several new glucose-lowering agents have been approved since 2005, and antihyperglycemic drug expenditure has increased by approximately 60% in Norway and the USA. Second, during the last decade several large studies comparing different treatment targets for diabetes have failed to show additional benefit from extremely intensive treatment targets. As a result of these studies modern diabetes guidelines emphasize the importance of individual treatment targets that may influence the overall quality of care. Finally, Norway offers government-funded healthcare services to all inhabitants, and these services are expected to provide high-quality diabetes care. We therefore designed a large cross-sectional survey in 2014, the ROSA 4 study, with the objective of assessing the current status of type 2 diabetes care in general practice and changes in the quality of care between 2005 and 2014, and identifying areas of care requiring improvement.

**RESEARCH DESIGN AND METHODS**

ROSA 4 is a population-based cross-sectional survey designed to assess the quality of care of patients with type 2 diabetes in general practice in Norway in 2014. We included patients with diabetes living in urban and rural areas in 5 of 19 counties, covering more than 50% of the general population in Norway. General practitioners (GPs) in these areas were invited to participate, and 77 practices (73% of the invited) with 282 GPs (77% of the invited) agreed (figure 1). Data were collected from the electronic patient records from all the GPs within a practice by research nurses.

All adults (≥18 years) with a diagnosis of diabetes (T89 and T90 in the International Classification of Primary Care) between 2012 and 2014 were identified using customized software that also captured predefined data from the electronic patient records. The records were examined manually by research nurses to verify electronically registered data and to collect data not suitable for electronic capture. Data capture was performed in January 2015–April 2016.

The following variables were registered in the survey: patient characteristics (age, sex, ethnicity, diabetes duration, height and weight, smoking status); processes of care (documentation of HbA1c, blood pressure, lipids, creatinine/estimated glomerular filtration rate (eGFR), height and weight, smoking habits, eye examination, albuminuria, monofilament test); medication (antihyperglycemic, antihypertensive, antithrombotic and lipid-lowering therapy extracted from the GP’s electronic prescription files); intermediate outcomes (HbA1c, blood pressure, cholesterol, low-density lipoprotein (LDL), creatinine/eGFR); and vascular complications (retinopathy, nephropathy (albuminuria, eGFR <60 mL/min/1.73 m²), neuropathy (pathological 10 g monofilament test), foot ulcer, lower limb amputation, coronary heart disease (angina, myocardial infarction, percutaneous coronary intervention/coronary artery bypass surgery), stroke (excluding transient ischemic attacks (TIA)), atrial fibrillation, and percutaneous transluminal angioplasty/arterial surgery). In the present study we included the last registered value in 2014 for most variables, except for eye examination, creatinine/eGFR and lipids (last registered 2012–2014).

![Figure 1](http://drc.bmj.com)
and smoking habits (last registered 2010–2014) (online supplementary table S1). Medication was extracted from the GP’s electronic prescriptions the last 15 months, October 1, 2013 to December 31, 2014.

Of the 11 428 patients in the electronic patient records with diabetes, 10 248 had type 2 diabetes. Patients who did not have their main follow-up in general practice (residential patients in nursing homes (n=63), patients attending a specialist clinic >1time/year (n=421), patients with a diabetes duration of less than 6 months and patients who had died or moved from the practice area during 2014 (n=300), in total n=784 (8%), were excluded from the analysis, leaving 9464 patients with type 2 diabetes for statistical analysis (figure 1).

The ROSA 3 survey in 2005 used the same inclusion and exclusion criteria and methods of data extraction as ROSA 4,20 30 and consisted of a sample of 5463 patients with type 2 diabetes treated in primary care, from 60 practices and 205 GPs (online supplementary figure 1). The ROSA 4 and ROSA 3 data sets used the same variable definition for almost all variables, except that the variable stroke excluded TIA in 2014, whereas TIA was included in 2005 (online supplementary table S1).

Quality of care was assessed against predefined review criteria based on key recommendations in the Norwegian 2009 guidelines31: HbA1c ≤7.0% (53 mmol/mol), intervention threshold blood pressure >140/85 mm Hg with treatment target ≤135/80 mm Hg, and total cholesterol ≤4.5 mmol/L. LDL targets were introduced with revision of the guidelines in 2009 but were not used in the comparison analyses due to missing data in the ROSA 3 survey.

Statistical analyses
We compared 2014 data with 2005 in regression models while controlling for patient age, gender and county of GP practice. We present average adjusted predictions with CIs adjusted for clustering within GP practices. Differences were tested for statistical significance using Wald tests. We did not control for diabetes duration since new patients may have been diagnosed at an earlier stage in the ROSA 4 study due to the introduction of HbA1c ≥6.5% (48 mmol/mol) as diagnostic criterion. All statistical analyses were performed using STATA/SE V.14.0 for Windows, with functions logit, mlogit and regress, and with margins and test postestimation procedures. In consideration of the large sample size and correspondingly high statistical power, we applied a somewhat strict criterion (P≤0.01) for statistical significance. In case of missing data, the percentages of valid cases and thus included cases are specified for each analysis.

In 2014, data were collected from two more counties than in 2005. We therefore performed a sensitivity analysis comparing data only from the three counties included in both ROSA 3 and 4. This analysis gave almost identical results for all variables (data not shown).

RESULTS

Study samples
In 2014, 73% of GP practices agreed to participate compared with 91% in 2005. We included 9464 (2014) and 5463 (2005) patients with type 2 diabetes. Characteristics of the study samples are presented in online supplementary table S2. There were more urban residents (85.2% vs 80.4%) and more men (54.6% vs 50.4%) included in 2014 compared with 2005, and the patients in 2014 also had a longer duration of diabetes (median duration 7 years vs 5 years). The samples were similar with regard to age, ethnicity, body mass index (BMI) and proportion of current smokers. The proportion of smokers was higher among patients ≤60 years vs ≥60 years in both 2014 (29.7% vs 19.3%) and 2005 (33.8% vs 20.4%).

Processes of care
HbA1c, blood pressure and cholesterol were measured in most patients (>85%) in both study years; however, HbA1c was performed in a lower proportion in 2014 compared with 2005 (86.4% vs 91.8%, adjusted change −4.4 percentage points, P<0.001) (table 1).

Frequencies of measurement of LDL and creatinine/ eGRF were also high in 2014, with 84.4% and 93.2% of patients, respectively. Recording of both height/weight to estimate BMI was low in both study years (44.6% in 2014), whereas registration of smoking habits increased (79.0% vs 56.0%, adjusted change +24.9 percentage points, P<0.001). Procedures related to screening for microvascular complications differed between 2014 and 2005, with fewer patients undergoing eye examination in 2014 (61.0% vs 71.5%, adjusted change −7.1 percentage points, P<0.001) and more patients undergoing the monofilament test (25.9% vs 18.7%, adjusted change +12.3 percentage points, P<0.001). Testing for albuminuria remained low (30.3%) in 2014.

Medication
Hyperglycemia was controlled by diet alone in approximately one-third of the patients in both surveys (table 2).

There was shift away from insulin in monotherapy toward other therapy schemes between 2005 and 2014 (P<0.001), and the overall frequency of the use of insulin also decreased (14.7% vs 22.2%, adjusted change −5.6 percentage points, P<0.001). Significantly more patients were on combination therapy involving more than two agents in 2014 (9.5% vs 1.8%, adjusted change +6.9 percentage points). Metformin was the most frequently used antihyperglycemic agent in 2014 (57.9%), and the use of metformin had increased substantially since 2005 (46.3%; adjusted change +9.6 percentage points, P<0.001). Use of sulfonylureas, on the other hand, was reduced (18.6% vs 30.7%, adjusted change −12.4 percentage points, P<0.001). New glucose-lowering agents were used by one-fifth of the patients in 2014. Sixty-six per cent of the patients received antihypertensive medication in both study years; however,
Table 1 Processes of care documented in patients with type 2 diabetes in general practice in Norway in 2014 (ROSA 4) and 2005 (ROSA 3)

| Processes of care                        | 2014 (n=9464) Percentages | 2005 (n=5463) Percentages | Change from 2005 to 2014 with 95% CI‡ |
|------------------------------------------|-----------------------------|-----------------------------|---------------------------------------|
|                                          | Observed, with 95% CI†      | Adjusted‡                   | Observed                             | Adjusted‡                             |
| HbA1c                                    | 86.4 (84.9 to 87.9)         | 86.8                        | 91.8                                 | 91.3                                  | -4.4 (-6.7 to -2.1)** |
| Blood pressure                           | 87.4 (85.8 to 89.0)         | 88.1                        | 89.7                                 | 88.7                                  | -0.5 (-3.2 to 2.2)  |
| Cholesterol                              | 89.0 (86.8 to 91.2)         | 89.0                        | 89.5                                 | 89.6                                  | -0.6 (-3.7 to 2.4)  |
| LDL                                      | 84.4 (81.1 to 87.7)         | 83.8                        | 40.8                                 | 41.7                                  | +42.1 (32.9 to 51.2)** |
| Creatinine/eGFR                          | 93.2 (91.5 to 95.0)         | NA                          | NA                                   | NA                                    |                       |
| Weight                                   | 51.4 (46.7 to 56.1)         | 51.8                        | 54.2                                 | 53.6                                  | -1.8 (-12.7 to 9.1)  |
| BMI                                      | 44.6 (40.0 to 49.3)         | 45.1                        | 36.9                                 | 36.3                                  | +8.8 (-1.9 to 19.5)  |
| Smoking habits                           | 79.0 (76.2 to 81.9)         | 79.6                        | 56.0                                 | 54.6                                  | +24.9 (18.3 to 31.5)** |
| Eye examination                          | 61.0 (57.4 to 64.6)         | 62.3                        | 71.5                                 | 69.4                                  | -7.1 (-11.1 to -3.2)** |
| Albuminuria                              | 30.3 (25.6 to 34.9)         | 31.3                        | 37.9                                 | 36.1                                  | -4.8 (-13.8 to 4.1)  |
| Monofilament 10g                         | 25.9 (21.5 to 30.3)         | 28.1                        | 18.7                                 | 15.8                                  | +12.3 (6.6 to 17.9)** |
| Number of screening procedures for microvascular complications§ | ** | ** | ** | ** | ** |
| 0                                        | 29.2 (25.7 to 32.8)         | 28.0                        | 21.2                                 | 22.8                                  | +5.2 (0.5 to 10.0)   |
| 1                                        | 36.3 (34.2 to 41.6)         | 35.5                        | 41.6                                 | 43.0                                  | -7.5 (-11.7 to -3.4) |
| 2                                        | 22.5 (20.0 to 25.0)         | 23.0                        | 25.7                                 | 24.6                                  | -1.6 (-6.5 to 3.2)   |
| 3                                        | 12.0 (9.1 to 14.8)          | 13.4                        | 11.6                                 | 9.6                                   | +3.9 (-0.8 to 8.6)   |

*P≤0.01, **P≤0.001.
†Based on data as registered, 95% CIs adjusted for clustering within GP practices.
‡Adjusted for sex, age, counties and clustering within GP practices.
§Screening procedures: eye examination, albuminuria and 10 g monofilament test.
BMI, body mass index; eGFR, estimated glomerular filtration rate; GP, general practitioner; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; NA, not available; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-Oslo-Salten-Akershus-Hordaland study.

Epidemiology/Health Services Research

the use of ACE/AII inhibitors, calcium blockers and thiazides all increased (all P≤0.001). The proportion of patients on lipid-lowering medication increased among patients with coronary heart disease (77.9% vs 67.5%, adjusted change +8.0 percentage points, P<0.001) as well as in general (54.5% vs 43.7%, adjusted change +11.3 percentage points, P<0.001).

Measurements and attained treatment targets

The patients achieved significantly more of the 2009 national treatment targets in 2014 than in 2005 (P<0.001), even though only 16.1% of the patients reached all three targets in 2014 (table 3). HbA1c ≤7.0% (≤53 mmol/mol) was achieved by 62.8% in 2014 vs 54.3% of the patients in 2005 (adjusted change +8.0 percentage points, P<0.001), although the mean HbA1c levels declined by only 0.2 percentage points (1.6 mmol/mol) (adjusted; P<0.001). Among patients on diet only, a high proportion attained the HbA1c target in both study years (85.8% in 2014), and in 2014 an improvement was seen among patients on medication (53.5% vs 43.7%, adjusted change +7.9 percentage points, P=0.001). The proportion with HbA1c >9.0% (>75 mmol/mol) was fairly stable (5.6% in 2014).

More patients met blood pressure targets (≤135/80 mm Hg on antihypertensive medication and ≤140/85 mm Hg without medication) in 2014 (50.3% vs 42.3%, adjusted change +7.2 percentage points, P=0.001), and the mean adjusted systolic blood pressure decreased by 3.3 mm Hg (P<0.001).

Substantially more patients also achieved the total cholesterol target (≤4.5 mmol/L) in 2014 (49.9% vs 33.5%, adjusted change +15.4 percentage points, P<0.001). Among patients on lipid-lowering medication, the proportions reaching target total cholesterol were in general higher and also increasing (65.3% vs 49.9%, adjusted change +13.7 percentage points, P<0.001). The 2009 treatment target for LDL was met by 51.9% of all patients in 2014; however, among patients with coronary heart disease, the proportion with LDL ≤1.8 mmol/L was substantially lower: 29.7%.

Vascular complications

The proportion of patients with coronary heart disease was relatively stable (22.0% in 2014) (table 4). There was a marked decrease in the proportion with neuropathy and with pathological monofilament test results among the relatively few patients registered...
Table 2  Overview of antihyperglycemic, antihypertensive, lipid-lowering and antithrombotic therapy in patients with type 2 diabetes in general practice in Norway in 2014 (ROSA 4) and 2005 (ROSA 3)

| Medication                                                                 | 2014 (n=9464) | 2005 (n=5463) | Change from 2005 to 2014 with 95% CI†‡ |
|----------------------------------------------------------------------------|---------------|---------------|--------------------------------------|
|                                                                            | 2014 percentages | 2005 percentages | Percentage points                     |
| **Antihyperglycemic therapy**                                             | Observed, with 95% CI§ Adjusted‡ | Observed Adjusted‡ |                                     |
| Diet only                                                                  | 31.7 (28.4 to 34.9) 32.5 | 28.2 27.0 | +5.5 (1.0 to 10.1)                   |
| Antihyperglycemic agents except for insulin                               | 53.6 (50.8 to 56.5) 52.2 | 49.6 52.3 | −0.1 (−4.2 to 4.1)                   |
| Insulin only                                                               | 5.4 (4.7 to 6.0) 5.6 | 12.4 11.6 | −6.0 (−7.9 to −4.2)                  |
| Insulin combined with other antihyperglycemic agents                       | 9.3 (8.4 to 10.2) 9.7 | 9.7 9.1 | +0.6 (−0.7 to 2.0)                   |
| **Groups of antihyperglycemic agents**                                    |               |               |                                      |
| Metformin                                                                  | 57.9 (54.7 to 61.1) 57.2 | 46.3 47.6 | +9.6 (5.2 to 14.1)**                  |
| Sulfonylurea                                                               | 18.6 (17.0 to 20.3) 18.5 | 30.7 31.0 | −12.4 (−15.7 to −9.1)**              |
| Insulin                                                                    | 14.7 (13.5 to 15.9) 15.3 | 22.2 20.9 | −5.6 (−8.2 to −3.1)****              |
| DPP-4 inhibitors                                                           | 13.9 (12.0 to 15.7) NA | NA |                                      |
| GLP1 analogs                                                               | 2.6 (2.1 to 3.1) NA | NA |                                      |
| SGLT2 inhibitors                                                           | 3.4 (2.5 to 4.4) NA | NA |                                      |
| **Numbers of antihyperglycemic agents, insulin included**                  |               |               |                                      |
| 1                                                                         | 36.2 (34.1 to 38.2) 36.0 | 43.8 44.4 | −8.4 (−11.7 to −5.0)                 |
| 2                                                                         | 22.7 (21.3 to 24.0) 22.5 | 26.2 26.6 | −4.2 (−6.6 to −1.7)                  |
| ≥3                                                                        | 9.5 (8.5 to 10.5) 9.0 | 1.8 2.1 | +6.9 (5.9 to 7.9)                    |
| **Antihypertensive agents**                                               |               |               |                                      |
| Antihypertensives                                                          | 65.9 (63.2 to 68.6) 65.9 | 66.4 66.4 | −0.5 (−3.9 to 2.9)                   |
| ACE/ArII inhibitors                                                        | 52.5 (50.1 to 54.8) 52.8 | 47.4 46.8 | +6.0 (2.3 to 9.6)**                  |
| Beta blockers                                                              | 30.5 (28.6 to 32.3) 30.7 | 31.2 30.9 | −0.3 (−3.0 to 2.5)                   |
| Calcium blockers                                                           | 25.9 (24.1 to 27.7) 26.6 | 22.2 21.2 | +5.4 (2.9 to 7.9)**                  |
| Thiazides                                                                  | 26.8 (25.1 to 28.6) 27.4 | 22.0 21.2 | +6.2 (3.5 to 9.0)**                  |
| **Number of antihypertensives**                                           |               |               |                                      |
| 1                                                                         | 19.2 (18.2 to 20.2) 19.1 | 20.0 20.2 | −1.1 (−2.9 to 0.8)                   |
| 2                                                                         | 20.3 (19.3 to 21.3) 20.2 | 19.5 19.6 | 0.6 (−1.2 to 2.4)                    |
| 3                                                                         | 16.4 (15.3 to 17.4) 16.5 | 14.5 14.3 | +2.2 (0.6 to 3.8)                    |
| ≥4                                                                        | 10.0 (8.9 to 11.1) 10.4 | 12.4 11.6 | −1.1 (−3.1 to 0.8)                   |
| Lipid-lowering medication                                                  | 54.5 (51.9 to 57.2) 54.7 | 43.7 43.4 | +11.3 (7.1 to 15.5)**                |
| With coronary heart disease                                               | 77.9 (74.3 to 81.5) 77.3 | 67.5 68.5 | +8.8 (3.4 to 14.2)**                 |
| Antithrombotic therapy                                                    | 36.9 (34.7 to 39.2) 37.3 | 40.3 39.7 | −2.5 (−6.0 to 1.1)                   |

Medication was extracted from the GP’s electronic prescriptions. For antithrombotic therapy 0.6% (n=33) were missing in 2005, and for all other medication groups data were available in 100% of the cases.

*P≤0.01, **P≤0.001.
†Based on data as registered, 95% CIs adjusted for clustering within GP practices.
‡Adjusted for sex, age, counties and clustering within GP practices.
DPP-4, Dipeptidyl peptidase-4; GLP1, Glucagon-like peptide-1; NA, not available; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-Oslo-Salten-Akershus-Hordaland study; SGLT2, Sodium-glucose co-transporter-2.

with these variables. Chronic kidney disease as evaluated by eGFR <60 mL/min was present in 17.3% of the patients in 2014, whereas 1.7% had eGFR of less than 30 mL/min.

**DISCUSSION**

We found clinically important improvements in the percentages attaining recommended targets for HbA1c, blood pressure and lipids in 2014 vs 2005. However, the
| Measurements and attained treatment targets | 2014 (n=9464) | 2005 (n=5463) | Change from 2005 to 2014 with 95% CI‡ |
|--------------------------------------------|---------------|---------------|-------------------------------------|
| **Measurements**                           | **Observed, with 95% CI†** | **Adjusted‡** | **Observed** | **Adjusted‡** | **Means or percentage points** |
| HbA1c                                      |               |               |                       |               |                               |
| %                                         | 86/92         | 7.0 (6.9 to 7.1) | 7.0 | 7.1 | 7.1 | −0.2 (−0.3 to −0.0)* |
| mmol/mol                                   | 86/92         | 52.9 (52.2 to 53.5) | 52.9 | 54.6 | 54.5 | −1.6 (−2.9 to −0.4)* |
| SBP (mm Hg)                                | 87/90         | 135.1 (134.2 to 136.0) | 135.3 | 138.9 | 138.6 | −3.3 (−4.8 to −1.8)** |
| DBP (mm Hg)                                | 86/90         | 78.0 (77.5 to 78.4) | 77.9 | 78.9 | 79.0 | −1.1 (−1.9 to −0.2)* |
| Cholesterol (mmol/L)                       | 89/89         | 4.7 (4.6 to 4.7) | 4.7 | 5.1 | 5.1 | −0.4 (−0.5 to −0.3)** |
| LDL (mmol/L)                               | 84/41         | 2.8 (2.7 to 2.8) | 2.8 | 3.1 | 3.1 | −0.3 (−0.4 to −0.3)** |
| **Targets**                                |               |               |                       |               |                               |
| HbA1c (%)(mmol/mol)                         |               |               |                       |               |                               |
| ≤7.0 (≤53)                                 | 86/92         | 62.8 (60.6 to 65.0) | 62.6 | 54.3 | 54.6 | +8.0 (3.8 to 12.1)** |
| Diet only                                  | 79/86         | 85.8 (83.1 to 88.5) | 85.9 | 83.7 | 83.5 | +2.4 (−1.5 to 6.4) |
| Medicated                                  | 90/94         | 53.5 (51.0 to 56.0) | 52.8 | 43.7 | 44.9 | +7.9 (3.1 to 12.6)** |
| ≤7.5 (≤58)                                 | 86/92         | 75.6 (74.6 to 77.5) | 75.4 | 69.4 | 69.6 | +5.8 (2.3 to 9.4)** |
| With CHD                                   | 87/92         | 74.3 (71.7 to 76.9) | 74.2 | 67.9 | 68.1 | +6.1 (1.2 to 11.0) |
| ≤8.0 (≤64)                                 | 86/92         | 85.6 (84.2 to 87.0) | 85.5 | 81.4 | 81.6 | +3.9 (1.5 to 6.2)** |
| With CHD                                   | 87/92         | 84.5 (82.3 to 86.7) | 84.4 | 80.2 | 80.4 | +4.1 (0.1 to 8.0) |
| >9.0 (>75)                                 | 86/92         | 5.6 (4.7 to 6.4) | 5.6 | 6.9 | 6.9 | −1.3 (−2.6 to −0.0) |
| Blood pressure                             |               |               |                       |               |                               |
| ≤135/80 mm Hg                              | 87/90         | 44.9 (41.9 to 47.9) | 44.7 | 36.6 | 37.0 | +7.7 (3.2 to 12.2)** |
| Medicated                                  | 92/94         | 41.3 (38.6 to 44.2) | 41.1 | 31.2 | 31.5 | +9.6 (5.1 to 14.1)** |
| >140/85 mm Hg                              | 79/82         | 29.7 (26.1 to 33.2) | 29.6 | 32.3 | 32.4 | −2.8 (−8.2 to 2.6) |
| Combined target§                           | 87/90         | 50.3 (47.5 to 53.0) | 50.0 | 42.3 | 42.8 | +7.2 (2.8 to 11.6)** |
| Lipids (mmol/L)                            |               |               |                       |               |                               |
| Cholesterol ≤4.5                           | 89/89         | 49.9 (48.2 to 51.6) | 49.5 | 33.5 | 34.1 | +15.4 (12.2 to 18.6)** |
| Medicated                                  | 94/96         | 65.3 (63.6 to 67.0) | 64.8 | 51.0 | 51.0 | +13.7 (10.0 to 17.4)** |
| LDL ≤2.5                                   | 84/41         | 46.3 (44.5 to 48.1) | 46.1 | 29.3 | 29.8 | +16.3 (12.4 to 20.2)** |
| Medicated                                  | 90/44         | 62.3 (60.7 to 64.0) | 62.1 | 44.8 | 46.1 | +16.0 (10.8 to 21.1)** |
| LDL≤1.8                                    | 85/36         | 29.7 (27.3 to 32.0) | 29.2 | 13.0 | 13.9 | +15.3 (11.8 to 18.7)** |

Continued
### Table 3 Continued

| Measurements and attained targets | 2014 (n=9464) Means or percentages | 2005 (n=5463) Means or percentages | Change from 2005 to 2014 with 95% CI‡‡ |
|----------------------------------|-------------------------------------|-------------------------------------|---------------------------------------|
|                                  | Valid cases, 2014/2005(%)           | Observed, with 95% CI†             | Adjusted‡                           | Observed | Adjusted‡ | Means or percentage points |
| LDL target 2009¶                 | 82/21                               | 51.9 (50.3 to 53.5)                | 51.8                                 | 6.4       | 6.6       | +45.2 (43.2 to 47.2)**     |
| Attained targets††               | 75/79                               | 10.5 (9.5 to 11.6)                 | 10.6                                 | 19.7      | 19.5      | −8.9 (−11.2 to −6.5)       |
| 0                                |                                     | 35.0 (33.3 to 36.7)                | 35.3                                 | 42.7      | 42.3      | −7.0 (−9.6 to −4.4)        |
| 1                                |                                     | 38.4 (37.1 to 39.7)                | 38.1                                 | 30.2      | 30.8      | +7.3 (4.9 to 9.7)          |
| 2                                |                                     | 16.1 (14.6 to 17.5)                | 16.1                                 | 7.4       | 7.5       | +8.6 (6.5 to 10.7)         |

*P≤0.01, **P≤0.001.
†Based on data as reported, 95% CIs were adjusted for clustering within GP practices.
‡Adjusted for sex, age, county and clustering within GP practices.
§Combined target: ≤135/80 mm Hg with antihypertensives or ≤140/85 mm Hg without antihypertensives.
¶For patients with cardiovascular disease: LDL ≤1.8 mmol/L. For patients without cardiovascular disease; LDL ≤2.5 mmol/L on lipid-lowering therapy, LDL ≤3.5 mmol/L without lipid-lowering therapy.
††For patients who have measured all of HbA1c, blood pressure and lipids: HbA1c ≤7.0% (53 mmol/mol), blood pressure ≤135/80 mm Hg and cholesterol ≤4.5 mmol/L.
CHD, coronary heart disease; DBP, diastolic blood pressure; GP, general practitioner; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-Oslo-Salten-Akershus-Hordaland study; SBP, systolic blood pressure.

### Study samples
We consider our findings to be representative for patients with type 2 diabetes treated by GPs in Norway. In both the ROSA 4 and ROSA 3 surveys, data were collected from Norway. In addition, national initiatives in the UK to improve care for people with diabetes BAI and in cross-sectional studies in the USA monitored, and with other recently published surveys from Europe and the US with respect to age, gender, diabetes duration, and with similar to the type 2 diabetes population in the comprehensive Swedish and Scottish population in the complete overlap. Furthermore, patients in the 2014 survey were similar to the type 2 diabetes population in the comprehensive Swedish and Scottish population in the complete overlap.
| Vascular complications of patients with type 2 diabetes in general practice in Norway in 2014 (ROSA 4) compared with 2005 (ROSA 3) |
|---------------------------------------------------------------|
| Complications                                                 | 2014 (n=9464) | 2005 (n=5463) | Change from 2005 to 2014 with 95% CI‡ |
|                                                              | Valid cases, 2014/2005 (%) | Percentages | Percentages Adjusted‡ | Observed, with 95% CI† Adjusted‡ |
| Microvascular complications                                  |                |              |                       |                           |
| Retinopathy§                                                 | 60/60          | 12.3 (11.1 to 13.4) | 12.2 | 14.6 | 14.8 | −2.6 (−5.1 to −0.1) |
| Neuropathy¶                                                  | 28/21          | 18.8 (15.8 to 21.8) | 17.8 | 33.2 | 37.4 | −19.6 (−25.5 to −13.7)** |
| Pathological monofilament††                                  | 26/19          | 10.6 (8.2 to 13.1) | 10.0 | 21.4 | 25.0 | −15.0 (−21.5 to −8.6)** |
| Foot ulcer                                                  | 100/100        | 2.7 (2.1 to 3.2) | 2.6 | 3.3 | 3.4 | −0.8 (−1.7 to 0.2) ** |
| Lower limb amputation                                        | 100/100        | 0.6 (0.5 to 0.8) | 0.6 | 0.4 | 0.5 | +0.1 (−0.1 to 0.4) |
| Nephropathy                                                  |                |                |                       |                           |
| Dialysis                                                    | 100/100        | 0.2 (0.1 to 0.3) | NA |                           |
| Kidney transplantation                                       | 100/100        | 0.2 (0.1 to 0.3) | NA |                           |
| CKD stage (eGFR, mL/min)                                     | 93/NA          | 11.2 (10.2 to 12.1) | NA |                           |
| 45–59                                                       | 11.2 (10.2 to 12.1) | NA |                           |
| 30–44                                                       | 4.4 (3.8 to 5.0) | NA |                           |
| 15–29                                                       | 1.5 (1.2 to 1.8) | NA |                           |
| <15                                                         | 0.2 (0.1 to 0.3) | NA |                           |
| Macrovascular complications                                  |                |                |                       |                           |
| Coronary heart disease‡‡                                     | 100/100        | 22.0 (21.0 to 22.9) | 22.7 | 25.7 | 24.3 | −1.6 (−3.2 to 0.0) |
| Stroke §§                                                    | 100/100        | 7.3 (6.6 to 7.9) | 7.4 | 10.2 | 10.0 | −2.6 (−3.8 to −1.3)** |
| PTA/arterial surgery                                         | 100/100        | 2.0 (1.6 to 2.3) | NA |                           |

*P≤0.01, **P≤0.001.
†Based on data as registered, 95% CIs adjusted for clustering within GP practices.
‡Adjusted for sex, age, county and clustering within GP practices.
§Non-proliferative/proliferative retinopathy stated in case notes regardless of time. Macular edema excluded.
¶Pathological monofilament test or foot ulcer or lower limb amputation.
††Pathological monofilament test ≥1/8.
‡‡Coronary heart disease: myocardial infarction, angina, revascularization.
§§Stroke: ischemic attack, transient ischemic attacks excluded in 2014, included in 2005.
CKD, chronic kidney disease, eGFR, estimated glomerular filtration rate; GP, general practitioner; NA, not available; PTA, percutaneous transluminal angioplasty; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-Oslo-Salten-Akershus-Hordaland study.
Medication, measurements and attained treatment targets

In accordance with national guidelines, the percentage of patients using metformin increased. The use of sulfonylureas decreased substantially (~12 percentage points). The same trends were seen in a recent publication from the USA.35

Risk factor control has improved during the last decade. The increase in achievement of HbA1c targets was similar to the observations between the periods 1999–2002 and 2007–2010 in NHANES (+8 percentage points).16 Compared with recent cross-sectional studies or annual reports from diabetes registries of type 2 diabetes in general practice worldwide, the proportion of patients achieving HbA1c <7.0% (<53 mmol/mol) in ROSA 4 was 57% vs 47%–52%.15,16,18,19 This confirms that glycemic control in Norwegian general practice is similar to other countries. We only found a slight improvement in mean HbA1c that was similar to findings in reports from the Swedish Diabetes Registry and NHANES.14,16 The decrease in mean HbA1c was only 0.2 percentage points (1.6 mmol/mol) despite the fact that antihyperglycemic drug expenditures increased by 60%. The relatively small decline in mean HbA1c seen during the last decade may be due to the reduction of the use of insulin. It is possible that the GPs postpone insulin treatment, and start with the new expensive antihyperglycemic agents, which have less glucose-lowering effect than insulin. During recent years guidelines have emphasized the need for individual glycemic treatment targets for patients with long diabetes duration and comorbidities.27–29 These targets are often less intensive than previously strict recommendations and may also explain the clinically insignificant change in mean HbA1c. Finally, mean HbA1c is now at such a low level that lower mean values are difficult to achieve in large study populations.

There was no significant decrease in BMI in 2014 compared with 2005 despite the introduction of weight-neutral and weight-reducing therapies. However, the proportion of patients on such therapies was relatively low in 2014 (Dipeptidyl peptidase 4 (DPP4) inhibitors 13.9%, Sodium-glucose co-transporter-2 (SGLT2) inhibitors, 3.4%, Glucagon-like peptide-1 (GLP1) analogs 2.6%). The increased use of ACE/II inhibitors, calcium blockers and thiazides probably explains the improved blood pressure control. However, there is still a high proportion of untreated patients above intervention threshold and treated patients above blood pressure targets. In our present study 38.5% achieved a blood pressure ≤130/80 mm Hg (regardless of medication) in 2014. Findings from other countries span from 33.8% (Scotland) and 41.6% (Swedish Diabetes Registry), to 51.3% (NHANES).15,16,19

The improved control of dyslipidemia might be influenced by the introduction of LDL targets in national guidelines in 2009.31 The proportion of patients on lipid-lowering therapy with cholesterol <4.5 mmol/L was similar in ROSA 4 and the Swedish Diabetes Registry (62.0% vs 59.0%), while the Swedish had a higher proportion with LDL <2.5 mmol/L (42.3% vs 52.6%). The use of statins in ROSA 4 was inferior to Sweden (54.3% vs 63.7%). Only 28.5% of patients with a history of CVD attained LDL target ≤1.8 mmol/L, similar to results from NHANES (27.5%).16 This indicates that more patients with diabetes should start lipid-lowering therapy in Norway and that GPs should maintain efforts to achieve the strict LDL target in high-risk persons with CVD.

Vascular complications

There was no significant change in the prevalence of coronary heart disease during the last decade in our study populations. This is similar to the findings in two recent cross-sectional surveys from the USA.33,35 The prevalence of microvascular complications in our study is subject to uncertainty due to poor recording of screening among GPs in both surveys (~60% eye examination, ~30% albuminuria test and ~25% monofilament test in 2014). We found no significant change in retinopathy between ROSA 4 and ROSA 3, but the 12.5% prevalence of patients with retinopathy in 2014 is probably underestimated due to inconsistent reporting. The Swedish Adult Diabetes Register reports a prevalence of retinopathy of 29.6% in their annual 2014 report. Their findings are probably more representative of retinopathy among patients with type 2 diabetes in general practice in Scandinavia.14 Fewer persons had neuropathy in ROSA 4 compared with ROSA 3, while more patients had a recorded monofilament test. The finding may be explained by selection bias if GPs in 2005 used monofilament test more frequently in patients suspected of having neuropathy. The prevalence of neuropathy in 2014 (18.8%) is in agreement with reports from the Swedish National Diabetes Register 2014 (21%), and both countries have ~2.7% with a history of foot ulcer. ROSA 4 and Scotland report similar percentages of lower limb amputation (0.6% and 0.7%, respectively). ROSA 4 and Scotland have the same proportion of patients with end-stage renal failure (0.6%).

Strengths and weaknesses

This study is one of the largest representative cross-sectional studies of type 2 diabetes in general practice performed in recent years, originating from a high-income country with an apparently well-organized healthcare system. Our study has some limitations. Screening procedures for microvascular complications are based on recorded data in the case notes. If GPs fail to record performed procedures, our results will overestimate the quality gaps. The level of albuminuria is not reported due to different measurement methods/units between GP practices, and frequent missing data. Finally, we excluded patients with main-follow up in specialist healthcare who probably had worse glycemic control; however, the absolute numbers were small and unlikely to influence the results (4.4% in 2014 vs 5.0% in 2005).
In summary, we found moderate improvements in blood pressure and lipid control during the last decade, which are similar to improvements reported from other countries. Improvements during the last decade are less striking than improvements reported in the previous decade. We demonstrated that there are still major gaps in the performance of recommended screening procedures to detect microvascular complications. Clinical performance in this area was considerably worse than other comparable countries. We also found a disturbingly high proportion of current smokers diverging from trends seen in the general Norwegian population. There is still considerable room for improvements of many aspects of diabetes care in general practice. Screening for microvascular complications must be improved. Risk factor control, especially the treatment of dyslipidemia, and the promotion of smoking cessation require attention. We suggest compulsory reporting to a national diabetes register and feedback to GPs as a means of continually evaluating diabetes control and promoting further improvements in diabetes care in Norway. A national screening program for diabetes retinopathy should also be considered.

REFERENCES

1. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 19,866 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117–25.
2. Holman RR, Sourni H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008–17.
3. Baij H, Zinnan B, Diabetes: Steno-2 - a small study with a big heart. Nat Rev Endocrinol 2016;12:692–4.
4. Eeg-Olofsson K, Zethelius B, Gudbjörnsdottir S, et al. Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register. Diab Vasc Dis Res 2016;13:268–77.
5. Gaede P, Oelgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298–307.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53.
7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study Group (UKPDS) Group. Lancet 1998;352:854–65.
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–13.
9. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015;373:1720–32.
10. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156–67.
11. Simmonds RK, Borch-Johnsen K, Lauritzen T, et al. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. Health Technol Assess 2016;20:1–86.
12. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:870–93.
13. Zounagou S, Arna H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes:
a meta-analysis of individual participant data from randomised controlled trials. *Lancet Diabetes Endocrinol* 2017;5:431–7.
14. Nationella Diabetes registret. Nationella diabetes registret 2014. https://www.ndr.nu/pdfs/Ansvarsprotokoll_ND_2014.pdf (accessed 1 Aug 2017).
15. Scottish Diabetes Survey. Scottish diabetes survey 2014, 2014. http://www.diabetesinscotland.org.uk/Publications/SDS2014. pdf (accessed 1 Aug 2017).
16. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. *N Engl J Med* 2013;368:1613–24.
17. Kloos C, Müller N, Hartmann P, et al. High quality of diabetes care based upon individualised treatment goals – a cross sectional study in 4784 patients in Germany. *Exp Clin Endocrinol Diabetes* 2016;124:294–9.
18. Miñambres I, Mediavilla JJ, Sarroca J, et al. Meeting individualized glycemic targets in primary care patients with type 2 diabetes in Spain. *BMC Endocr Disord* 2016;16:10.
19. Yokoyama H, Oishi M, Takamura H, et al. Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes ([JDDM 40]). *BMJ Open Diabetes Res Care* 2016;4:e000294.
20. Claudi T, Ingskog W, Cooper JG, et al. [Quality of diabetes care in Norwegian general practice]. *Tidsskr Nor Laegeforen* 2008;128:2570–4.
21. Jenum AK, Claudi T, Cooper JG. Primary care diabetes in Norway. *Prim Care Diabetes* 2008;2:203–5.
22. Folkehelseinstituttet. Reseptregistret. http://www.reseptregisteret.no/(accessed 1 Aug 2017).
23. Turner LW, Narrey D, Stafford RS, et al. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. *Diabetes Care* 2014;37:985–92.
24. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545–59.
25. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560–72.
26. Duckworth W, Abrair A, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360:129–39.
27. Helsedirektoratet. Nasjonal fagligretninglinje for diabetes, 2016. https://helsedirektoratet.no/retningslinjer/diabetes(accessed 1 Aug 2017).
28. NICE. NICE guidelines NG28, 2016. https://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations(accessed 1 Aug 2017).
29. American Diabetes Association. 9. Cardiovascular disease and risk management. *Diabetes Care* 2017;40:S75–S87.
30. Cooper JG, Claudi T, Jenum AK, et al. Quality of care for patients with type 2 diabetes in primary care in Norway is improving: results of cross-sectional surveys of 33 general practices in 1995 and 2005. *Diabetes Care* 2009;32:81–3.
31. Helsedirektoratet. Nasjonal faglig retninglinje med anbefalinger om forebygging, diagnostikk og behandling av diabetes, 2009. https://helsedirektoratet.no/retningslinjer/diabetes-nasjonal-faglig-retningslinje(accessed 1 Aug 2017).
32. Pérez A, Mediavilla JJ, Miñambres I, et al. Glycemic control in patients with type 2 diabetes mellitus in Spain. *Rev Clin Esp* 2014;214:429–36.
33. Pantalone KM, Hobbs TM, Wells BJ, et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. *BMJ Open Diabetes Res Care* 2015;3:e00093.
34. Ali MK, Singh K, Kondal D, et al. Effectiveness of a multicomponent quality improvement strategy to improve achievement of diabetes care goals: A randomized, controlled trial. *Ann Intern Med* 2016;165:399–408.
35. Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. *Diabetes Care* 2017;40:468–75.
36. Healthcare Quality Improvement Partnership. National diabetes audit, 2015. http://www.diabetesaudit.org.uk/resources/national-diabetes-audit-2013-2014-2015-report-1-care-processes-and-treatment-targets(accessed 1 Aug 2017).
37. UK Department of Health. Six years on: Delivering the diabetes national service framework, 2010. http://webarchive.nationalarchives.gov.uk/20130107105537/http://www.dh.gov.uk/en/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/DH_112509(accessed 1 Aug 2017).
38. Margeirsdottir HD, Larsen JR, Kummernes SJ, et al. The establishment of a new national network leads to quality improvement in childhood diabetes: implementation of the ISPAD Guidelines. *Pediatr Diabetes* 2010;11:88–95.
39. Folkehelseinstituttet. Røyking, 2014. https://www.fhi.no/ml/roycling/royk-og-snus-faktaark-med-statist/(accessed 1 Aug 2017).